vTv Therapeutics

vTv Therapeutics is a clinical-stage biopharmaceutical company based in High Point, North Carolina, dedicated to the discovery and development of orally administered small molecule therapeutics aimed at addressing unmet medical needs. The company has a diverse pipeline that includes drug candidates for various conditions, particularly focusing on central nervous system disorders, including Alzheimer's disease, and metabolic disorders such as type 2 diabetes. Key products under development include Azeliragon, which is in Phase II clinical trials for mild Alzheimer's disease, and TTP399, a liver-selective glucokinase activator that has shown promising results in treating type 2 diabetes. Other candidates such as TTP273, HPP737, HPP971, and HPP3033 are also being explored for chronic diseases. vTv Therapeutics emphasizes innovative technology and strategic collaborations to advance its research and development efforts, aiming to translate protein modulation into effective treatments. The company operates as a subsidiary of MacAndrews & Forbes Incorporated and was previously known as TransTech Pharma before rebranding in 2015.